Vaccines or candidate vaccines used to prevent bacillary dysentery (DYSENTERY, BACILLARY) caused by species of SHIGELLA.
A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria that ferments sugar without gas production. Its organisms are intestinal pathogens of man and other primates and cause bacillary dysentery (DYSENTERY, BACILLARY).
A bacterium which is one of the etiologic agents of bacillary dysentery (DYSENTERY, BACILLARY) and sometimes of infantile gastroenteritis.
DYSENTERY caused by gram-negative rod-shaped enteric bacteria (ENTEROBACTERIACEAE), most often by the genus SHIGELLA. Shigella dysentery, Shigellosis, is classified into subgroups according to syndrome severity and the infectious species. Group A: SHIGELLA DYSENTERIAE (severest); Group B: SHIGELLA FLEXNERI; Group C: SHIGELLA BOYDII; and Group D: SHIGELLA SONNEI (mildest).
A lactose-fermenting bacterium causing dysentery.
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that is extremely pathogenic and causes severe dysentery. Infection with this organism often leads to ulceration of the intestinal epithelium.
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
One of the SHIGELLA species that produces bacillary dysentery (DYSENTERY, BACILLARY).
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.
Two or more vaccines in a single dosage form.
Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.
Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.
Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.
An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated.
A genus of REOVIRIDAE, causing acute gastroenteritis in BIRDS and MAMMALS, including humans. Transmission is horizontal and by environmental contamination. Seven species (Rotaviruses A thru G) are recognized.
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.
Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.
Strains of ESCHERICHIA COLI that produce or contain at least one member of either heat-labile or heat-stable ENTEROTOXINS. The organisms colonize the mucosal surface of the small intestine and elaborate their enterotoxins causing DIARRHEA. They are mainly associated with tropical and developing countries and affect susceptible travelers to those places.
An ENTEROTOXIN from VIBRIO CHOLERAE. It consists of two major protomers, the heavy (H) or A subunit and the B protomer which consists of 5 light (L) or B subunits. The catalytic A subunit is proteolytically cleaved into fragments A1 and A2. The A1 fragment is a MONO(ADP-RIBOSE) TRANSFERASE. The B protomer binds cholera toxin to intestinal epithelial cells, and facilitates the uptake of the A1 fragment. The A1 catalyzed transfer of ADP-RIBOSE to the alpha subunits of heterotrimeric G PROTEINS activates the production of CYCLIC AMP. Increased levels of cyclic AMP are thought to modulate release of fluid and electrolytes from intestinal crypt cells.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)

Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine. (1/33)

The invasiveness and virulence of Shigella spp. are largely due to the expression of plasmid-encoded virulence factors, among which are the invasion plasmid antigens (Ipa proteins). After infection, the host immune response is directed primarily against lipopolysaccharide (LPS) and the virulence proteins (IpaB, IpaC, and IpaD). Recent observations have indicated that the Ipa proteins (IpaB, IpaC, and possibly IpaD) form a multiprotein complex capable of inducing the phagocytic event which internalizes the bacterium. We have isolated a complex of invasins and LPS from water-extractable antigens of virulent shigellae by ion-exchange chromatography. Western blot analysis of the complex indicates that all of the major virulence antigens of Shigella, including IpaB, IpaC, and IpaD, and LPS are components of this macromolecular complex. Mice or guinea pigs immunized intranasally with purified invasin complex (invaplex), without any additional adjuvant, mounted a significant immunoglobulin G (IgG) and IgA antibody response against the Shigella virulence antigens and LPS. The virulence-specific response was very similar to that previously noted in primates infected with shigellae. Guinea pigs (keratoconjunctivitis model) or mice (lethal lung model) immunized intranasally on days 0, 14, and 28 and challenged 3 weeks later with virulent shigellae were protected from disease (P<0.01 for both animal models).  (+info)

Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. (2/33)

Data suggest that the O-specific polysaccharide (O-SP) domain of the lipopolysaccharide (LPS) of Shigella species is both an essential virulence factor and a protective antigen and that a critical level of serum immunoglobulin G (IgG) to this antigen will confer immunity to shigellosis. Because covalent attachment of polysaccharides to proteins increases their immunogenicity, especially in infants and in young children, the O-SP of Shigella species were bound to medically useful proteins, and the safety and immunogenicity of the resultant conjugates were confirmed in adults and 4- to 7-year-old children. Succinylation of the carrier protein improved the immunogenicity of Shigella conjugates in mice and increased their yield. Based on these results, a clinical trial of O-SP conjugates of Shigella sonnei and Shigella flexneri 2a bound to succinylated mutant Pseudomonas aeruginosa exotoxin A (rEPAsucc) or native or succinylated Corynebacterium diphtheriae toxin mutant (CRM9 or CRM9succ) was conducted in healthy adults. The conjugates were safe and immunogenic. S. sonnei-CRM9, S. sonnei-CRM9succ, and S. sonnei-rEPAsucc elicited significant rises of geometric mean (GM) IgG anti-LPS within 1 week of injection (P < 0.001). At 26 weeks, the GM anti-LPS levels elicited by these three conjugates were similar and higher than their prevaccination levels (P < 0.0001). GM IgG anti-LPS levels elicited by S. flexneri 2a-rEPAsucc were significantly higher than those elicited by S. flexneri 2a-rCRM9succ at all intervals after injection. At 26 weeks, the levels of IgG anti-LPS in vaccinees were higher than their prevaccination levels (P < 0.0001). The serum antibody responses were specific, as there was no significant rise of anti-LPS to the heterologous O-SP in any vaccinee. Both conjugates elicited statistically significant rises of serum antibodies to the injected carrier protein. At 6 months, these five Shigella conjugates elicited higher fold rises than similar conjugates (D. N. Taylor et al., Infect. Immun. 61:3678-3687, 1993). Based on these data, we chose S. sonnei-CRM9 and S. flexneri 2a-rEPAsucc for evaluation in children.  (+info)

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. (3/33)

We studied the safety and immunogenicity of a Shigella flexneri 2a vaccine comprising native S. flexneri 2a lipopolysaccharide (LPS) complexed to meningococcal outer membrane proteins-proteosomes-in normal, healthy adults. A two-dose series of immunizations was given by intranasal spray, and doses of 0.1, 0.4, 1.0, and 1.5 mg (based on protein) were studied in a dose-escalating design. The vaccine was generally well tolerated. The most common reactions included rhinorrhea and nasal stuffiness, which were clearly dose related (P < or = 0.05). These reactions were self-limited and generally mild. The vaccine elicited S. flexneri 2a LPS-specific immunoglobulin A (IgA), IgG, and IgM antibody-secreting cells (ASCs) in a dose-responsive manner. At doses of 1.0 or 1.5 mg, highly significant (P < 0.001) increases in ASCs of all antibody isotypes occurred and 95% of subjects had an ASC response in at least one antibody isotype. Dose-related serum antibody responses were observed, with geometric mean two- to fivefold rises in specific serum IgA and IgG titers and two- to threefold rises in IgM in the 1.0- and 1.5-mg-dose groups (P < 0.0001 for each isotype). Elevated serum antibody levels persisted through day 70. Increases in fecal IgG and IgA and also in urinary IgA specific for S. flexneri 2a LPS were demonstrated. These were most consistent and approached statistical significance (P = 0.02 to 0.12 for various measures) on day 70 after the first dose. The magnitude of immune responses to intranasally administered proteosome-S. flexneri 2a LPS vaccine is similar to those reported for live vaccine candidates associated with protective efficacy in human challenge models, and further evaluation of this product is warranted.  (+info)

Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. (4/33)

We conducted a phase I trial with healthy adults to evaluate WRSS1, a live, oral Delta virG Shigella sonnei vaccine candidate. In a double-blind, randomized, dose-escalating fashion, inpatient volunteers received a single dose of either placebo (n = 7) or vaccine (n = 27) at 3 x 10(3) CFU (group 1), 3 x 10(4) CFU (group 2), 3 x 10(5) CFU (group 3), or 3 x 10(6) CFU (group 4). The vaccine was generally well tolerated, although a low-grade fever or mild diarrhea occurred in six (22%) of the vaccine recipients. WRSS1 was recovered from the stools of 50 to 100% of the vaccinees in each group. The geometric mean peak anti-lipopolysaccharide responses in groups 1 to 4, respectively, were 99, 39, 278, and 233 for immunoglobulin (IgA) antibody-secreting cell counts; 401, 201, 533, and 284 for serum reciprocal IgG titers; and 25, 3, 489, and 1,092 for fecal IgA reciprocal titers. Postvaccination increases in gamma interferon production in response to Shigella antigens occurred in some volunteers. We conclude that WRSS1 vaccine is remarkably immunogenic in doses ranging from 10(3) to 10(6) CFU but elicits clinical reactions that must be assessed in further volunteer trials.  (+info)

Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine. (5/33)

WRSd1 is a Shigella dysenteriae 1 vaccine containing deletions of the virG(icsA) gene required for intercellular spreading and a 20-kb chromosomal region encompassing the Shiga toxin genes (stxAB). WRSd1 was constructed from S. dysenteriae 1 strain 1617 that was originally isolated during the 1968 to 1969 epidemic of Shiga dysentery in Guatemala. The virG(icsA) deletion was constructed from a streptomycin-resistant (Str(r)) mutant of 1617 by a filter mating procedures using a virG(icsA) deletion derivative, pDeltavirG2. A colony that was invasive for HeLa cells and negative for the virG(icsA) gene by Southern blotting was grown anaerobically on plates containing chlorate for selection of resistant colonies that had lost the entire Shiga toxin gene. A virG(icsA) stxAB Str(r) mutant selected from the chlorate plates was designated WRSd1. This candidate vaccine was evaluated for safety, immunogenicity, and protective efficacy using the guinea pig keratoconjunctivitis model. WRSd1 was Sereny negative, and two applications of this strain to the cornea elicited a significant protective immune response against the S. dysenteriae 1 O antigen. Vaccination with WRSd1 conferred protection against challenge with each of three virulent S. dysenteriae 1 strains. Since a vaccine protecting against multiple Shigella species is required for most areas where Shigella is endemic, protection studies using a combination vaccine of Shigella sonnei vaccine strain WRSS1, Shigella flexneri 2a vaccine strain SC602, and WRSd1 were also performed. Guinea pigs vaccinated with a mixture of equal amounts of the three vaccine strains were protected against challenge with each of the homologous virulent strains. Unlike WRSS1 and SC602, however, the level of protection afforded by WRSd1 in a combination vaccine was lower than the protection elicited by a pure culture. A current Good Manufacturing Practice product of WRSd1 given intragastrically to rhesus monkeys proved safe and immunogenic.  (+info)

Molecular cloning and characterization of genes for Shigella sonnei form I O polysaccharide: proposed biosynthetic pathway and stable expression in a live salmonella vaccine vector. (6/33)

The gene region for biosynthesis of Shigella sonnei form I O polysaccharide (O-Ps) and flanking sequences, totaling >18 kb, was characterized by deletion analysis to define a minimal construct for development of Salmonella-based live vaccine vector strains. Lipopolysaccharide (LPS) expression and DNA sequence studies of plasmid deletion derivatives indicated form I O-Ps expression from a 12.3-kb region containing a putative promoter and 10 contiguous open reading frames (ORFs), one of which is the transposase of IS630. A detailed biosynthetic pathway, consistent with the predicted functions of eight of the nine essential ORFs and the form I O-Ps structure, is proposed. Further sequencing identified partial IS elements (i.e., IS91 and IS630) and wzz upstream of the form I coding region and a fragment of aqpZ and additional full or partial IS elements (i.e., IS629, IS91, and IS911) downstream of this region. The stability of plasmid-based form I O-Ps expression was greater from low-copy vectors than from high-copy vectors and was enhanced by deletion of the downstream IS91 from plasmid inserts. Both core-linked (i.e., LPS) and non-core-linked (i.e., capsule-like) surface expression of form I O-Ps were detected by Western blotting and silver staining of polyacrylamide gel electrophoresis-separated Shigella and Escherichia coli extracts. However, salmonellae, which have a core that is chemically dissimilar to that of shigellae, expressed only non-core-linked surface-associated form I O-Ps. Finally, attenuated Salmonella enterica serovar Typhi live vaccine vector candidates, containing minimal-sized form I operon constructs, elicited immune protection in mice against virulent S. sonnei challenge, thereby supporting the promise of live, oral vaccines for the prevention of shigellosis.  (+info)

Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. (7/33)

We report the first community-based evaluation of Shigella flexneri 2a strain SC602, a live, oral vaccine strain attenuated by deletion of the icsA (virG) plasmid virulence gene, given at 10(4) CFU. The primary objectives of this trial were to determine the safety and immunogenicity of the vaccine and to determine the duration of colonization. Four of 34 volunteers experienced transient fevers, and three reported diarrhea during the first 3 days of the study. Half of the volunteers mounted a positive serum immunoglobulin A (IgA) response to S. flexneri lipopolysaccharide. All but one of the volunteers excreted the vaccine in their stools for 1 to 33 days, and this excretion was often intermittent. Data from the community-based study were supplemented with an inpatient trial in which three volunteers received 10(3) and nine received 10(4) CFU. All volunteers who received 10(3) CFU excreted SC602 and had an IgA antibody-secreting cell response. Two of these had a serum IgA response. Six of the nine volunteers who received 10(4) CFU excreted SC602. One vaccinee had a transient fever and two met the definition of diarrhea. Six volunteers that received 10(4) CFU had an antibody-secreting cell response, and four had a serum IgA response. SC602 has now been tested at 10(4) CFU in a total of 58 volunteers. The cumulative results of these clinical trials, reported here and previously (Coster et al., Infect. Immun. 67:3437-3443, 1999), have demonstrated that SC602 is a substantially attenuated candidate vaccine that can evoke protection against the most severe symptoms of shigellosis in a stringent human challenge model of disease.  (+info)

Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. (8/33)

BACKGROUND: We created a live, attenuated, oral Shigella vaccine by constructing a lineage of guanine auxotrophs and conducted a double-blind, placebo-controlled trial to ascertain (1) the attenuation profile of Delta guaBA Shigella flexneri 2a, which harbors deletions in the guanine nucleotide synthesis pathway (CVD 1204); (2) additional attenuation conferred by deletions in set and sen genes encoding Shigella enterotoxins (ShETs) 1 and 2, respectively (CVD 1208); and (3) the relative immunogenicity of these constructs. METHODS: Inpatient volunteers received a single oral dose of CVD 1204, CVD 1208 (10(7), 10(8), or 10(9) cfu), or placebo. Clinical, immunologic, and microbiologic responses were evaluated. RESULTS: Reactogenicity occurred in 8 of 23 recipients of CVD 1204, characterized by diarrhea (30%), fever (22%), and/or dysentery (17%), but in only 1 (5%) of 21 recipients of CVD 1208 (brief fever) (P=.02, Fisher's exact test). Antilipopolysaccharide responses, as measured by antibody-secreting cell, serum, or fecal antibody levels, occurred in 67%, 71%, and 100% of recipients of CVD 1204 and in 86%, 43%, and 100% of recipients of CVD 1208 at doses of 10(7), 10(8), and 10(9) cfu, respectively. CONCLUSIONS: We conclude that 1 or both ShETs are virulence determinants in humans; their inactivation, in combination with Delta guaBA, leads to a well-tolerated and immunogenic Shigella vaccine candidate.  (+info)

Shigella vaccines are immunizations that are developed to protect against Shigella infection, which is caused by the bacterium Shigella spp. These vaccines aim to stimulate the immune system to produce an immune response (the production of antibodies and activation of immune cells) that will provide protection against future Shigella infections.

There are currently no licensed Shigella vaccines available for use, although several candidate vaccines are in various stages of development and clinical trials. These vaccines typically contain inactivated or attenuated (weakened) forms of the bacteria, or specific components of the bacteria that can stimulate an immune response.

Shigella infection can cause a range of symptoms, including diarrhea, fever, abdominal cramps, and tenesmus (the strong, frequent urge to have a bowel movement). In severe cases, it can lead to complications such as dehydration, seizures, and hemolytic-uremic syndrome (HUS), which is a serious condition that can cause kidney failure. Shigella infection is most commonly transmitted through contaminated food or water, or direct contact with an infected person's feces.

Shigella is a genus of Gram-negative, facultatively anaerobic, rod-shaped bacteria that are primarily responsible for causing shigellosis, also known as bacillary dysentery. These pathogens are highly infectious and can cause severe gastrointestinal illness in humans through the consumption of contaminated food or water, or direct contact with an infected person's feces.

There are four main species of Shigella: S. dysenteriae, S. flexneri, S. boydii, and S. sonnei. Each species has distinct serotypes that differ in their epidemiology, clinical presentation, and antibiotic susceptibility patterns. The severity of shigellosis can range from mild diarrhea to severe dysentery with abdominal cramps, fever, and tenesmus (the strong, frequent urge to defecate). In some cases, Shigella infections may lead to complications such as bacteremia, seizures, or hemolytic uremic syndrome.

Preventive measures include maintaining good personal hygiene, proper food handling and preparation, access to clean water, and adequate sanitation facilities. Antibiotic treatment is generally recommended for severe cases of shigellosis, but the emergence of antibiotic-resistant strains has become a growing concern in recent years.

Shigella flexneri is a species of Gram-negative, facultatively anaerobic, rod-shaped bacteria that belongs to the family Enterobacteriaceae. It is one of the four species of the genus Shigella, which are the causative agents of shigellosis, also known as bacillary dysentery.

Shigella flexneri is responsible for causing a significant proportion of shigellosis cases worldwide, particularly in developing countries with poor sanitation and hygiene practices. The bacteria can be transmitted through the fecal-oral route, often via contaminated food or water, and can cause severe gastrointestinal symptoms such as diarrhea, abdominal cramps, fever, and tenesmus (the urgent need to defecate).

The infection can lead to inflammation of the mucous membrane lining the intestines, resulting in the destruction of the epithelial cells and the formation of ulcers. In severe cases, Shigella flexneri can invade the bloodstream and cause systemic infections, which can be life-threatening for young children, the elderly, and immunocompromised individuals.

The diagnosis of Shigella flexneri infection typically involves the detection of the bacteria in stool samples using culture methods or molecular techniques such as PCR. Treatment usually involves antibiotics, although resistance to multiple drugs has been reported in some strains. Preventive measures include good hygiene practices, safe food handling, and access to clean water.

Bacillary dysentery is a type of dysentery caused by the bacterium Shigella. It is characterized by the inflammation of the intestines, particularly the colon, resulting in diarrhea that may contain blood and mucus. The infection is typically spread through contaminated food or water, or close contact with an infected person. Symptoms usually appear within 1-4 days after exposure and can include abdominal cramps, fever, nausea, vomiting, and tenesmus (the strong, frequent urge to have a bowel movement). In severe cases, bacillary dysentery can lead to dehydration, electrolyte imbalance, and other complications. Treatment typically involves antibiotics to kill the bacteria, as well as fluid replacement to prevent dehydration.

"Shigella sonnei" is a medically recognized term that refers to a specific species of bacteria that can cause human illness. It's one of the four main species in the genus Shigella, and it's responsible for a significant portion of shigellosis cases worldwide.

Shigella sonnei is a gram-negative, facultative anaerobic, non-spore forming, rod-shaped bacterium that can be transmitted through the fecal-oral route, often via contaminated food or water. Once ingested, it can invade and infect the epithelial cells of the colon, leading to inflammation and diarrhea, which can range from mild to severe.

The infection caused by Shigella sonnei is known as shigellosis, and its symptoms may include abdominal cramps, fever, nausea, vomiting, and watery or bloody diarrhea. In some cases, it can lead to more serious complications such as dehydration, seizures, or hemolytic uremic syndrome (HUS), a type of kidney failure.

It's worth noting that Shigella sonnei is particularly concerning because it has developed resistance to multiple antibiotics, making treatment more challenging in some cases. Proper hygiene practices, such as handwashing and safe food handling, are crucial in preventing the spread of this bacterium.

"Shigella dysenteriae" is a specific species of bacteria that can cause severe forms of dysentery, a type of diarrheal disease. The infection caused by this bacterium is known as shigellosis. Shigella dysenteriae is highly infectious and can be transmitted through direct contact with an infected person or through contaminated food or water.

The bacteria produce toxins that can cause inflammation and damage to the lining of the intestine, leading to symptoms such as diarrhea (often containing blood and mucus), abdominal cramps, fever, and tenesmus (the urgent need to have a bowel movement). In severe cases, shigellosis can lead to complications such as dehydration, seizures, and hemolytic-uremic syndrome (HUS), a serious condition that can cause kidney failure.

Shigella dysenteriae is a public health concern, particularly in areas with poor sanitation and hygiene practices. Prevention measures include good hand hygiene, safe food handling practices, and access to clean water. Treatment typically involves antibiotics, fluids, and electrolyte replacement to manage symptoms and prevent complications.

Bacterial vaccines are types of vaccines that are created using bacteria or parts of bacteria as the immunogen, which is the substance that triggers an immune response in the body. The purpose of a bacterial vaccine is to stimulate the immune system to develop protection against specific bacterial infections.

There are several types of bacterial vaccines, including:

1. Inactivated or killed whole-cell vaccines: These vaccines contain entire bacteria that have been killed or inactivated through various methods, such as heat or chemicals. The bacteria can no longer cause disease, but they still retain the ability to stimulate an immune response.
2. Subunit, protein, or polysaccharide vaccines: These vaccines use specific components of the bacterium, such as proteins or polysaccharides, that are known to trigger an immune response. By using only these components, the vaccine can avoid using the entire bacterium, which may reduce the risk of adverse reactions.
3. Live attenuated vaccines: These vaccines contain live bacteria that have been weakened or attenuated so that they cannot cause disease but still retain the ability to stimulate an immune response. This type of vaccine can provide long-lasting immunity, but it may not be suitable for people with weakened immune systems.

Bacterial vaccines are essential tools in preventing and controlling bacterial infections, reducing the burden of diseases such as tuberculosis, pneumococcal disease, meningococcal disease, and Haemophilus influenzae type b (Hib) disease. They work by exposing the immune system to a harmless form of the bacteria or its components, which triggers the production of antibodies and memory cells that can recognize and fight off future infections with that same bacterium.

It's important to note that while vaccines are generally safe and effective, they may cause mild side effects such as pain, redness, or swelling at the injection site, fever, or fatigue. Serious side effects are rare but can occur, so it's essential to consult with a healthcare provider before receiving any vaccine.

Attenuated vaccines consist of live microorganisms that have been weakened (attenuated) through various laboratory processes so they do not cause disease in the majority of recipients but still stimulate an immune response. The purpose of attenuation is to reduce the virulence or replication capacity of the pathogen while keeping it alive, allowing it to retain its antigenic properties and induce a strong and protective immune response.

Examples of attenuated vaccines include:

1. Sabin oral poliovirus vaccine (OPV): This vaccine uses live but weakened polioviruses to protect against all three strains of the disease-causing poliovirus. The weakened viruses replicate in the intestine and induce an immune response, which provides both humoral (antibody) and cell-mediated immunity.
2. Measles, mumps, and rubella (MMR) vaccine: This combination vaccine contains live attenuated measles, mumps, and rubella viruses. It is given to protect against these three diseases and prevent their spread in the population.
3. Varicella (chickenpox) vaccine: This vaccine uses a weakened form of the varicella-zoster virus, which causes chickenpox. By introducing this attenuated virus into the body, it stimulates an immune response that protects against future infection with the wild-type virus.
4. Yellow fever vaccine: This live attenuated vaccine is used to prevent yellow fever, a viral disease transmitted by mosquitoes in tropical and subtropical regions of Africa and South America. The vaccine contains a weakened form of the yellow fever virus that cannot cause the disease but still induces an immune response.
5. Bacillus Calmette-Guérin (BCG) vaccine: This live attenuated vaccine is used to protect against tuberculosis (TB). It contains a weakened strain of Mycobacterium bovis, which does not cause TB in humans but stimulates an immune response that provides some protection against the disease.

Attenuated vaccines are generally effective at inducing long-lasting immunity and can provide robust protection against targeted diseases. However, they may pose a risk for individuals with weakened immune systems, as the attenuated viruses or bacteria could potentially cause illness in these individuals. Therefore, it is essential to consider an individual's health status before administering live attenuated vaccines.

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. It typically contains an agent that resembles the disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it encounters in the future.

Vaccines can be prophylactic (to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight disease that is already present). The administration of vaccines is called vaccination. Vaccinations are generally administered through needle injections, but can also be administered by mouth or sprayed into the nose.

The term "vaccine" comes from Edward Jenner's 1796 use of cowpox to create immunity to smallpox. The first successful vaccine was developed in 1796 by Edward Jenner, who showed that milkmaids who had contracted cowpox did not get smallpox. He reasoned that exposure to cowpox protected against smallpox and tested his theory by injecting a boy with pus from a cowpox sore and then exposing him to smallpox, which the boy did not contract. The word "vaccine" is derived from Variolae vaccinae (smallpox of the cow), the term devised by Jenner to denote cowpox. He used it in 1798 during a conversation with a fellow physician and later in the title of his 1801 Inquiry.

Shigella boydii is a subgroup or species of the genus Shigella, which are gram-negative, rod-shaped bacteria that can cause gastrointestinal illness in humans. The illness caused by S. boydii, as well as other Shigella species, is known as shigellosis or bacillary dysentery.

S. boydii is further divided into several subgroups or serotypes based on their surface antigens. This bacterium is primarily transmitted through the fecal-oral route, often via contaminated food or water, and can cause symptoms such as diarrhea (often with blood and mucus), abdominal cramps, fever, and vomiting.

Shigellosis caused by S. boydii tends to be less common compared to other Shigella species like S. dysenteriae, S. flexneri, and S. sonnei. However, the severity of the illness can vary widely, with some individuals experiencing mild symptoms while others may develop severe, life-threatening complications, particularly in young children, the elderly, and those with weakened immune systems.

Inactivated vaccines, also known as killed or non-live vaccines, are created by using a version of the virus or bacteria that has been grown in a laboratory and then killed or inactivated with chemicals, heat, or radiation. This process renders the organism unable to cause disease, but still capable of stimulating an immune response when introduced into the body.

Inactivated vaccines are generally considered safer than live attenuated vaccines since they cannot revert back to a virulent form and cause illness. However, they may require multiple doses or booster shots to maintain immunity because the immune response generated by inactivated vaccines is not as robust as that produced by live vaccines. Examples of inactivated vaccines include those for hepatitis A, rabies, and influenza (inactivated flu vaccine).

A viral vaccine is a biological preparation that introduces your body to a specific virus in a way that helps your immune system build up protection against the virus without causing the illness. Viral vaccines can be made from weakened or inactivated forms of the virus, or parts of the virus such as proteins or sugars. Once introduced to the body, the immune system recognizes the virus as foreign and produces an immune response, including the production of antibodies. These antibodies remain in the body and provide immunity against future infection with that specific virus.

Viral vaccines are important tools for preventing infectious diseases caused by viruses, such as influenza, measles, mumps, rubella, polio, hepatitis A and B, rabies, rotavirus, chickenpox, shingles, and some types of cancer. Vaccination programs have led to the control or elimination of many infectious diseases that were once common.

It's important to note that viral vaccines are not effective against bacterial infections, and separate vaccines must be developed for each type of virus. Additionally, because viruses can mutate over time, it is necessary to update some viral vaccines periodically to ensure continued protection.

Synthetic vaccines are artificially produced, designed to stimulate an immune response and provide protection against specific diseases. Unlike traditional vaccines that are derived from weakened or killed pathogens, synthetic vaccines are created using synthetic components, such as synthesized viral proteins, DNA, or RNA. These components mimic the disease-causing agent and trigger an immune response without causing the actual disease. The use of synthetic vaccines offers advantages in terms of safety, consistency, and scalability in production, making them valuable tools for preventing infectious diseases.

I could not find a specific medical definition for "Vaccines, DNA." However, I can provide you with some information about DNA vaccines.

DNA vaccines are a type of vaccine that uses genetically engineered DNA to stimulate an immune response in the body. They work by introducing a small piece of DNA into the body that contains the genetic code for a specific antigen (a substance that triggers an immune response). The cells of the body then use this DNA to produce the antigen, which prompts the immune system to recognize and attack it.

DNA vaccines have several advantages over traditional vaccines. They are relatively easy to produce, can be stored at room temperature, and can be designed to protect against a wide range of diseases. Additionally, because they use DNA to stimulate an immune response, DNA vaccines do not require the growth and culture of viruses or bacteria, which can make them safer than traditional vaccines.

DNA vaccines are still in the experimental stages, and more research is needed to determine their safety and effectiveness. However, they have shown promise in animal studies and are being investigated as a potential tool for preventing a variety of infectious diseases, including influenza, HIV, and cancer.

Combined vaccines are defined in medical terms as vaccines that contain two or more antigens from different diseases, which are given to provide protection against multiple diseases at the same time. This approach reduces the number of injections required and simplifies the immunization schedule, especially during early childhood. Examples of combined vaccines include:

1. DTaP-Hib-IPV (e.g., Pentacel): A vaccine that combines diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b (Hib) disease, and poliovirus components in one injection to protect against these five diseases.
2. MMRV (e.g., ProQuad): A vaccine that combines measles, mumps, rubella, and varicella (chickenpox) antigens in a single injection to provide immunity against all four diseases.
3. HepA-HepB (e.g., Twinrix): A vaccine that combines hepatitis A and hepatitis B antigens in one injection, providing protection against both types of hepatitis.
4. MenACWY-TT (e.g., MenQuadfi): A vaccine that combines four serogroups of meningococcal bacteria (A, C, W, Y) with tetanus toxoid as a carrier protein in one injection for the prevention of invasive meningococcal disease caused by these serogroups.
5. PCV13-PPSV23 (e.g., Vaxneuvance): A vaccine that combines 13 pneumococcal serotypes with PPSV23, providing protection against a broader range of pneumococcal diseases in adults aged 18 years and older.

Combined vaccines have been thoroughly tested for safety and efficacy to ensure they provide a strong immune response and an acceptable safety profile. They are essential tools in preventing various infectious diseases and improving overall public health.

An AIDS vaccine is a type of preventive vaccine that aims to stimulate the immune system to produce an effective response against the human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS). The goal of an AIDS vaccine is to induce the production of immune cells and proteins that can recognize and eliminate HIV-infected cells, thereby preventing the establishment of a persistent infection.

Despite decades of research, there is still no licensed AIDS vaccine available. This is due in part to the unique challenges posed by HIV, which has a high mutation rate and can rapidly evolve to evade the immune system's defenses. However, several promising vaccine candidates are currently being tested in clinical trials around the world, and researchers continue to explore new approaches and strategies for developing an effective AIDS vaccine.

Conjugate vaccines are a type of vaccine that combines a part of a bacterium with a protein or other substance to boost the body's immune response to the bacteria. The bacterial component is usually a polysaccharide, which is a long chain of sugars that makes up part of the bacterial cell wall.

By itself, a polysaccharide is not very immunogenic, meaning it does not stimulate a strong immune response. However, when it is conjugated or linked to a protein or other carrier molecule, it becomes much more immunogenic and can elicit a stronger and longer-lasting immune response.

Conjugate vaccines are particularly effective in protecting against bacterial infections that affect young children, such as Haemophilus influenzae type b (Hib) and pneumococcal disease. These vaccines have been instrumental in reducing the incidence of these diseases and their associated complications, such as meningitis and pneumonia.

Overall, conjugate vaccines work by mimicking a natural infection and stimulating the immune system to produce antibodies that can protect against future infections with the same bacterium. By combining a weakly immunogenic polysaccharide with a protein carrier, these vaccines can elicit a stronger and more effective immune response, providing long-lasting protection against bacterial infections.

A subunit vaccine is a type of vaccine that contains a specific piece or component of the microorganism (such as a protein, sugar, or part of the bacterial outer membrane), instead of containing the entire organism. This piece of the microorganism is known as an antigen, and it stimulates an immune response in the body, allowing the development of immunity against the targeted infection without introducing the risk of disease associated with live vaccines.

Subunit vaccines offer several advantages over other types of vaccines. They are generally safer because they do not contain live or weakened microorganisms, making them suitable for individuals with weakened immune systems or specific medical conditions that prevent them from receiving live vaccines. Additionally, subunit vaccines can be designed to focus on the most immunogenic components of a pathogen, potentially leading to stronger and more targeted immune responses.

Examples of subunit vaccines include the Hepatitis B vaccine, which contains a viral protein, and the Haemophilus influenzae type b (Hib) vaccine, which uses pieces of the bacterial polysaccharide capsule. These vaccines have been crucial in preventing serious infectious diseases and reducing associated complications worldwide.

Vaccination is a simple, safe, and effective way to protect people against harmful diseases, before they come into contact with them. It uses your body's natural defenses to build protection to specific infections and makes your immune system stronger.

A vaccination usually contains a small, harmless piece of a virus or bacteria (or toxins produced by these germs) that has been made inactive or weakened so it won't cause the disease itself. This piece of the germ is known as an antigen. When the vaccine is introduced into the body, the immune system recognizes the antigen as foreign and produces antibodies to fight it.

If a person then comes into contact with the actual disease-causing germ, their immune system will recognize it and immediately produce antibodies to destroy it. The person is therefore protected against that disease. This is known as active immunity.

Vaccinations are important for both individual and public health. They prevent the spread of contagious diseases and protect vulnerable members of the population, such as young children, the elderly, and people with weakened immune systems who cannot be vaccinated or for whom vaccination is not effective.

Malaria vaccines are biological preparations that induce immunity against malaria parasites, thereby preventing or reducing the severity of malaria disease. They typically contain antigens (proteins or other molecules derived from the parasite) that stimulate an immune response in the recipient, enabling their body to recognize and neutralize the pathogen upon exposure.

The most advanced malaria vaccine candidate is RTS,S/AS01 (Mosquirix), which targets the Plasmodium falciparum parasite's circumsporozoite protein (CSP). This vaccine has shown partial protection in clinical trials, reducing the risk of severe malaria and hospitalization in young children by about 30% over four years. However, it does not provide complete immunity, and additional research is ongoing to develop more effective vaccines against malaria.

Papillomavirus vaccines are vaccines that have been developed to prevent infection by human papillomaviruses (HPV). HPV is a DNA virus that is capable of infecting the skin and mucous membranes. Certain types of HPV are known to cause cervical cancer, as well as other types of cancer such as anal, penile, vulvar, and oropharyngeal cancers. Other types of HPV can cause genital warts.

There are currently two papillomavirus vaccines that have been approved for use in the United States: Gardasil and Cervarix. Both vaccines protect against the two most common cancer-causing types of HPV (types 16 and 18), which together cause about 70% of cervical cancers. Gardasil also protects against the two most common types of HPV that cause genital warts (types 6 and 11).

Papillomavirus vaccines are given as a series of three shots over a period of six months. They are most effective when given to people before they become sexually active, as this reduces the risk of exposure to HPV. The Centers for Disease Control and Prevention (CDC) recommends that all boys and girls get vaccinated against HPV at age 11 or 12, but the vaccine can be given to people as young as age 9 and as old as age 26.

It is important to note that papillomavirus vaccines do not protect against all types of HPV, and they do not treat existing HPV infections or cervical cancer. They are intended to prevent new HPV infections and the cancers and other diseases that can be caused by HPV.

Cholera is an infectious disease caused by the bacterium Vibrio cholerae, which is usually transmitted through contaminated food or water. The main symptoms of cholera are profuse watery diarrhea, vomiting, and dehydration, which can lead to electrolyte imbalances, shock, and even death if left untreated. Cholera remains a significant public health concern in many parts of the world, particularly in areas with poor sanitation and hygiene. The disease is preventable through proper food handling, safe water supplies, and improved sanitation, as well as vaccination for those at high risk.

Rotavirus is a genus of double-stranded RNA virus in the Reoviridae family, which is a leading cause of severe diarrhea and gastroenteritis in young children and infants worldwide. The virus infects and damages the cells lining the small intestine, resulting in symptoms such as vomiting, watery diarrhea, abdominal cramps, and fever.

Rotavirus is highly contagious and can be spread through contact with infected individuals or contaminated surfaces, food, or water. The virus is typically transmitted via the fecal-oral route, meaning that it enters the body through the mouth after coming into contact with contaminated hands, objects, or food.

Rotavirus infections are often self-limiting and resolve within a few days to a week, but severe cases can lead to dehydration, hospitalization, and even death, particularly in developing countries where access to medical care and rehydration therapy may be limited. Fortunately, there are effective vaccines available that can prevent rotavirus infection and reduce the severity of symptoms in those who do become infected.

Diarrhea is a condition in which an individual experiences loose, watery stools frequently, often exceeding three times a day. It can be acute, lasting for several days, or chronic, persisting for weeks or even months. Diarrhea can result from various factors, including viral, bacterial, or parasitic infections, food intolerances, medications, and underlying medical conditions such as inflammatory bowel disease or irritable bowel syndrome. Dehydration is a potential complication of diarrhea, particularly in severe cases or in vulnerable populations like young children and the elderly.

According to the World Health Organization (WHO), Rotavirus is the most common cause of severe diarrhea among children under 5 years of age. It is responsible for around 215,000 deaths among children in this age group each year.

Rotavirus infection causes inflammation of the stomach and intestines, resulting in symptoms such as vomiting, watery diarrhea, and fever. The virus is transmitted through the fecal-oral route, often through contaminated hands, food, or water. It can also be spread through respiratory droplets when an infected person coughs or sneezes.

Rotavirus infections are highly contagious and can spread rapidly in communities, particularly in settings where children are in close contact with each other, such as child care centers and schools. The infection is usually self-limiting and resolves within a few days, but severe cases can lead to dehydration and require hospitalization.

Prevention measures include good hygiene practices, such as handwashing with soap and water, safe disposal of feces, and rotavirus vaccination. The WHO recommends the inclusion of rotavirus vaccines in national immunization programs to reduce the burden of severe diarrhea caused by rotavirus infection.

Rotavirus vaccines are preventive measures used to protect against rotavirus infections, which are the leading cause of severe diarrhea and dehydration among infants and young children worldwide. These vaccines contain weakened or inactivated forms of the rotavirus, a pathogen that infects and causes symptoms by multiplying inside cells lining the small intestine.

The weakened or inactivated virus in the vaccine stimulates an immune response in the body, enabling it to recognize and fight off future rotavirus infections more effectively. The vaccines are usually administered orally, as a liquid droplet or on a sugar cube, to mimic natural infection through the gastrointestinal tract.

There are currently two licensed rotavirus vaccines available globally:

1. Rotarix (GlaxoSmithKline): This vaccine contains an attenuated (weakened) strain of human rotavirus and is given in a two-dose series, typically at 2 and 4 months of age.
2. RotaTeq (Merck): This vaccine contains five reassortant viruses, combining human and animal strains to provide broader protection. It is administered in a three-dose series, usually at 2, 4, and 6 months of age.

Rotavirus vaccines have been shown to significantly reduce the incidence of severe rotavirus gastroenteritis and related hospitalizations among infants and young children. The World Health Organization (WHO) recommends the inclusion of rotavirus vaccination in national immunization programs, particularly in countries with high child mortality rates due to diarrheal diseases.

Enterotoxigenic Escherichia coli (ETEC) is a type of diarrheagenic E. coli that causes traveler's diarrhea and diarrheal diseases in infants in developing countries. It produces one or two enterotoxins, known as heat-labile toxin (LT) and heat-stable toxin (ST), which cause the intestinal lining to secrete large amounts of water and electrolytes, resulting in watery diarrhea. ETEC is often transmitted through contaminated food or water and is a common cause of traveler's diarrhea in people traveling to areas with poor sanitation. It can also cause outbreaks in refugee camps, nursing homes, and other institutional settings. Prevention measures include avoiding consumption of untreated water and raw or undercooked foods, as well as practicing good personal hygiene.

Cholera toxin is a protein toxin produced by the bacterium Vibrio cholerae, which causes the infectious disease cholera. The toxin is composed of two subunits, A and B, and its primary mechanism of action is to alter the normal function of cells in the small intestine.

The B subunit of the toxin binds to ganglioside receptors on the surface of intestinal epithelial cells, allowing the A subunit to enter the cell. Once inside, the A subunit activates a signaling pathway that results in the excessive secretion of chloride ions and water into the intestinal lumen, leading to profuse, watery diarrhea, dehydration, and other symptoms associated with cholera.

Cholera toxin is also used as a research tool in molecular biology and immunology due to its ability to modulate cell signaling pathways. It has been used to study the mechanisms of signal transduction, protein trafficking, and immune responses.

An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.

GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine * LimmaTech in-licenses Shigella ... We have been a part of the Shigella vaccine programs journey together with GSK and the Wellcome Trust and the agreement ... Partnering with the team at LimmaTech Bio to further the development of this Shigella vaccine candidate is a great example of ... "LimmaTech Bio has remained committed to developing our Shigella vaccine candidate and this agreement with GSK has its roots in ...
... and 6 and Shigella sonnei. Gates MRI will have an exclusive license for manufacture and commercialization of the vaccine in 73 ... and license agreement to jointly develop a quadrivalent synthetic carbohydrate-based conjugate vaccine against Shigella ... GAVI low-income countries, thereby furthering Gates MRIs mission of preventing or mitigating infections caused by Shigella. ... Bill & Melinda Gates Medical Research Institute and the Institut Pasteur to Develop a Novel Vaccine Against Shigella. ...
But there is no substantial evidence of efficacy for ETEC and shigella vaccines, although several promising vaccine concepts ... The estimated effect of cholera, shigella, Enterotoxigenic Escherichia coli (ETEC) and rotavirus vaccines was determined by ... A total of 24 papers were selected and analyzed for all the four vaccines. Based on the evidence, we propose a 74% mortality ... We did not find sufficient evidence and a suitable outcome to project mortality reductions for cholera, ETEC and shigella in ...
Shigella vaccine development has mainly focused on serotype-targeted vaccines that are based on Shigella O antigen (15). Thus, ... An update on vaccines against Shigella. Ther Adv Vaccines. 2013;1:113-23. DOIPubMedGoogle Scholar ... Whole genome analysis to detect potential vaccine-induced changes on Shigella sonnei genome. Vaccine. 2015;33:2978-83. DOI ... von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, et al. A multicentre study of Shigella diarrhoea in six Asian countries ...
Shigella Vaccines Market to Reach $574.20 Million in 2021, CAGR of 6.4% Forecasted till 2028. 2 months ago ...
Shigella organisms are a group of gram-negative, facultative intracellular pathogens. They were recognized as the etiologic ... attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun. ... Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit. Infect Immun. 2011 Dec. 79(12 ... Shigella were discovered over 100 years ago by a Japanese microbiologist named Shiga, for whom the genus is named. Shigella was ...
Vaccine profiles: Shigella 29 Nov 2023 5 min read. ... It is also the part of the virus used in most COVID-19 vaccines ... Sigal wrote on Twitter that BA.4/BA.5 escape, while not as dramatic as Omicron escape from the vaccine or Delta immunity, "is ... By clicking the Subscribe button, you are agreeing to receive the digital newsletter from Gavi, the Vaccine Alliance, ... significantly enhance its ability to overcome the immunity provided by vaccines or previous infection, or render diagnostic ...
Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Dani Cohen, Shai Ashkenazi, ... Dive into the research topics of Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli ...
Here, we aimed to identify novel immunogenic Shigella antigens that could serve as Shigella vaccine candidates, either alone, ... These findings provide six novel immunogenic Shigella proteins that could serve as candidate vaccine antigens, species-specific ... or when conjugated to Shigella O-antigen. Using a reverse vaccinology approach, where genomic analysis informed the Shigella ... Several Shigella antigens displayed IgG and IgA seroconversion, with no difference in sero-reactivity across by sex or age. IgG ...
No vaccines are available for Shigella. The best prevention against shigellosis is thorough, frequent, and cautious handwashing ... Shigella sonnei at MicrobeWiki Shigella sonnei in the NCBI Taxonomy Browser Type strain of Shigella sonnei at BacDive - the ... Shigella sonnei is a species of Shigella. Together with Shigella flexneri, it is responsible for 90% of shigellosis cases. ... "General Information , Shigella - Shigellosis , CDC". www.cdc.gov. 2017-10-12. Mayo Clinic Staff. "Shigella Infection". Shigella ...
Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference. Vaccine. 2017 Dec 14;35( ... Vaccines against Shigella and enterotoxigenic Escherichia coli : A summary of the 2016 VASE Conference. In: Vaccine. 2017 ; Vol ... Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference. Vaccine, 35(49), 6775- ... Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference, Vaccine, vol. 35, no. ...
Glycoconjugates and use thereof as vaccines against Shigella flexneri serotype 3a and X. ... Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri (SF6) ... Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri ...
This topic was the subject of a workshop at the 2018 Vaccines Against Shigella and ETEC (VASE) conference, in the context of O- ... This topic was the subject of a workshop at the 2018 Vaccines Against Shigella and ETEC (VASE) conference, in the context of O- ... This topic was the subject of a workshop at the 2018 Vaccines Against Shigella and ETEC (VASE) conference, in the context of O- ... This topic was the subject of a workshop at the 2018 Vaccines Against Shigella and ETEC (VASE) conference, in the context of O- ...
For the first time, (S. flexneri) 2b serotype BGCs vaccine was prepared by incubation with Triton X-100 (TX100) for only 12& ... However, a clinical study is needed to confirm the efficacy and total safety of this novel vaccine. ... both bacterial ghost vaccines (BGVs) were safe and effective, according to the results of the safety check tests and ... The IgG levels of the bacterial ghost-vaccinated groups were four and three times greater for the TX100 and TW80 ghost vaccines ...
Shigella flexneri infection: pathogenesis and vaccine development. FEMS Microbiol Rev (2004) 28(1):43-58. doi:10.1016/j.femsre. ... Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World ... 53). (C) Confocal time-lapse images of Tg(mpeg1:G/U:nfsb-mCherry) larva (red macrophages) infected with Shigella flexneri ( ... The zebrafish as a new model for the in vivo study of Shigella flexneri interaction with phagocytes and bacterial autophagy. ...
Several vaccine candidates targeting ETEC or Shigella are in various stages of development.[31][32] ... The oral cholera vaccine, while effective for prevention of cholera, is of questionable use for prevention of TD.[6] A 2008 ... Shigella spp. and Salmonella spp. are other common bacterial pathogens. Campylobacter, Yersinia, Aeromonas, and Plesiomonas spp ... Jelinek T, Kollaritsch H (2008). "Vaccination with Dukoral against travelers diarrhea (ETEC) and cholera". Expert Rev Vaccines ...
Nanoparticles, Oral Sub unit vaccine, Shigella and Badminton. + - Additional Information Click to collapse ... The only prophylactic measure against such disease it to develop vaccine and prevent the disease from happening. In line my ... research topic is to develop nanoparticles based SUB-UNIT ORAL VACCINE against diarrhoea for children. On successful completion ...
Categories: Shigella Vaccines Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, CopyrightRestricted 9 ...
Shigella organisms are a group of gram-negative, facultative intracellular pathogens. They were recognized as the etiologic ... attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun. ... Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit. Infect Immun. 2011 Dec. 79(12 ... encoded search term (Shigella Infection) and Shigella Infection What to Read Next on Medscape ...
The World Market What are the trends that are fueling a new boom in vaccine production and sales? Why is an industry so - ... Shigella. *West Nile Virus. *THE WORLD MARKET FOR ADULT PREVENTIVE VACCINES*Total Market Size and Forecast*Table World Market ... DTaP & DTP Vaccines *Hep Vaccines *HiB Vaccines *MMR Vaccines *Combination Vaccines *Pneumococcal Vaccines *Polio Vaccines * ... Influenza Vaccines *Hepatitis Vaccines *Pneumococcal Vaccines *Travel, DT and other Adult Vaccines Additionally, this report ...
Bacteria called Shigella can cause food poisoning that results in diarrhea and stomach pain. Prevention is better than ... Researchers are working on vaccines against Shigella bacteria but havent developed one yet. ... What is Shigella infection?. Shigellosis, or Shigella infection caused by Shigella bacteria, is a disease that affects your ... Who does Shigella infection affect?. Anyone can be infected with Shigella, but it often occurs in regions with poor sanitation ...
... a vaccine program designed to prevent Shigella. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which ... Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of ... Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the ... Vaxcytes pipeline also includes VAX-31, a 31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate designed to ...
To reduce the risk of sexual transmission of Shigella, sex partners should thoroughly wash their hands and body before and ... Adults and children without confirmed immunity should be vaccinated with 2 doses of measles vaccine, especially prior to ... In the United States, most Shigella infections occur in young children and their care-takers and are due to a species called S ... Shigella is a common bacterial cause of diarrhea in the United States; typical symptoms include bloody or watery diarrhea, ...
Shigella organisms: 3 vaccines have been shown to be immunogenic and protective in field trials. Parenteral vaccines may be ... Currently, 2 vaccines have been approved: a live oral vaccine, RotaTeq, made by Merck for use in children, and GSKs Rotarix. ... A new, cheaper killed-cell vaccine is likely to be available soon; oral cholera vaccines are still being investigated, and ... Prevention of Diarrhea With Vaccines. *Salmonella typhi: 2 typhoid vaccines (with limited cost effectiveness) are currently ...
... of an orthogonally-protected pentasaccharide for use as a glycan precursor in a Shigella flexneri 3a conjugate vaccine: ...
CDC Releases New Studies on Jynneos Vaccine Effectiveness in Preventing Mpox Outbreaks May 18, 2023 ... Shigella is a stomach bug that can cause severe diarrhea, stomach cramps, and fever.[2] Symptoms typically start a day or two ... CDC Alert: Rise in Extensively Drug-Resistant Shigella Infections. The Centers for Disease Control and Prevention (CDC) have ... The CDC recommends that healthcare professionals be vigilant about suspecting and reporting cases of XDR Shigella infection to ...
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World ...
Gastrointestinal (enteric) diseases (vaccine-preventable). Rubella (German measles). Respiratory diseases (vaccine-preventable) ... Shigellosis (Shigella). Food- and water-borne illnesses (food poisoning). Shingles (herpes-varicella zoster). Skin infections ( ... Respiratory diseases (vaccine-preventable). Foodborne diseases (food poisoning). Food- and water-borne illnesses (food ... Sexually transmitted infections (vaccine-preventable). Hypertension - see High blood pressure. Heart and circulation conditions ...

No FAQ available that match "shigella vaccines"

No images available that match "shigella vaccines"